Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,166.00+0.42%ETH$2,520.35+3.03%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
AR

NASDAQ · ARVN

Arvinas, Inc.

Healthcare · Biotechnology

$8.71

Down-$0.26 (-2.99%)

Updated Sep 11, 2026, 10:39 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
974.25M
P/E ratio
-10.66
Dividend yield
0.00%
52-week range
$6.97 – $14.51
Volume
776.73K
Avg. volume
876.56K

Price performance

ARVN price history

1M range · 20 trading sessions · Daily adjusted prices

ARVN closed at $8.71 after 20 trading sessions, down 3.33% for the selected period.

Last close
$8.71
Period change
-3.33%
Period low
$8.71
Period high
$9.68
Daily close
View OHLC price history
ARVN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$8.67$8.775$8.47$8.71776.73K
Sep 9, 2026$9.085$9.10$8.75$8.76738.47K
Sep 8, 2026$9.23$9.34$8.97$9.08570.72K
Sep 4, 2026$9.31$9.455$9.22$9.39449.3K
Sep 3, 2026$9.68$9.691$9.21$9.31501.48K
Sep 2, 2026$9.28$9.64$9.27$9.59548.8K
Sep 1, 2026$9.14$9.30$9.0601$9.28491.14K
Aug 31, 2026$9.12$9.27$8.9601$9.20659.72K
Aug 28, 2026$9.17$9.235$9.03$9.18600.34K
Aug 27, 2026$9.27$9.43$9.15$9.24527.01K
Aug 26, 2026$9.53$9.545$9.28$9.32532.59K
Aug 25, 2026$9.39$9.74$9.39$9.60530.61K
Aug 24, 2026$9.28$9.39$9.06$9.34500.36K
Aug 21, 2026$9.02$9.39$9.00$9.365951.75K
Aug 20, 2026$9.55$9.63$8.97$9.025601.73K
Aug 19, 2026$9.44$9.69$9.44$9.68494.21K
Aug 18, 2026$9.19$9.3317$9.10$9.26554.73K
Aug 17, 2026$8.91$9.26$8.894$9.20584.03K
Aug 14, 2026$8.91$8.975$8.72$8.97461.29K
Aug 13, 2026$8.91$9.09$8.855$9.01939.14K

Latest ARVN news

The latest Smart Investors Daily articles mentioning ARVN.

Stock researchCompany · Overview

ARVN research

Overview

Company profile and research snapshot.

Company profile

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.20
Implied upside
—
Analysts
—
ARVN recent ratings
DateFirmRatingTarget
Aug 10, 2026CitigroupBuy—
Aug 10, 2026Evercore ISI GroupOutperform—
Aug 5, 2026WedbushNeutral—
Aug 5, 2026Wells FargoEqual-Weight—
Aug 4, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that that management will participate in fireside chats at the following upcoming investor conferences: Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at 1:30 p.m. ET; webcast available here. Cantor Global Healthcare Conference on Thursday, Septe

Yahoo · Sep 1, 2026

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Grant Date”) and in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock inc

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By